Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
General information only, not medical advice. This page describes what public sources say about a supply event; it does not tell any clinic or patient what to use.
Short answer: is the IV fluid shortage over?
In part. On August 8, 2025, the FDA Commissioner announced that “the shortage of sodium chloride 0.9% injection products has resolved,” and those products were removed from the Current Shortages list in the FDA Drug Shortage Database. The same statement says other IV fluids remain in shortage and that FDA will keep monitoring supply. So the answer to “is there still a saline shortage?” depends on which product you mean: the 0.9% saline shortage ended in FDA’s records; the wider IV fluid category was not declared over.
Definition and scope
“IV fluid shortage” is the common name for the 2024-2025 supply disruption of large-volume parenteral fluids, the bagged solutions given through a vein, such as 0.9% sodium chloride (normal saline), 5% and 10% glucose (dextrose) and combinations of the two. Searchers also use “saline shortage” and “IV bag shortage.” These are related but not identical: the first names a drug product, the second names the container. FDA’s August 2025 resolution covers the drug product, sodium chloride 0.9% injection. It does not speak to every fluid, and it does not address devices such as empty IV bags, which were tracked separately (see the timeline).
Why IV fluids are fragile: the Baxter North Cove event
The American Hospital Association (AHA) reports that Hurricane Helene damaged Baxter’s North Cove, North Carolina plant on September 27, 2024, and describes Baxter as producing about 60% of U.S. IV solutions. When a large share of a sterile, high-volume product comes from one site, a single outage can affect hospitals nationwide. These products are also sterile injectables supplied in sealed containers, so output cannot be improvised: the container has to stay intact for the contents to stay sterile. The FDA statement credits FDA, the Administration for Strategic Preparedness and Response (ASPR) and industry partners for the recovery; it does not itself mention Baxter or Helene.
Timeline: what happened and when
| Date | Event | Source |
|---|---|---|
| Sept 27, 2024 | Helene damages Baxter’s North Cove plant | AHA |
| Oct 21, 2024 | Baxter letter: coordinating with FDA to temporarily import IV fluids from its Shanghai, China facility | Baxter letter hosted by FDA |
| Dec 4, 2024 | FDA adds empty IV bags to the Medical Device Shortages List (estimated through March 2025) | AHA |
| Dec 5, 2024 | Baxter resumes all 3-L irrigation and peritoneal dialysis lines | AHA |
| Dec 19, 2024 | “Nearly all” North Cove lines restarted | AHA |
| Jan 22, 2025 | Allocations for two sodium chloride IV solutions raised to 100% | AHA |
| Aug 8, 2025 | FDA announces the 0.9% sodium chloride shortage resolved | FDA |
How FDA and hospitals responded
FDA’s statement lists three levers: temporary importation of product after scientific and regulatory assessment, expedited reviews to increase manufacturing capacity, and extension of product expiry dates.
What the imported-product letter said
The Baxter letter is the clearest primary record of what imported fluids looked like at the point of use. Read as a checklist of what the document states, not as advice:
- Not FDA-approved. The letter says FDA has not approved the products made at Baxter’s Shanghai facility; they were imported temporarily to prevent a shortage of large-volume parenteral fluids.
- Products covered. 0.9% Sodium Chloride Injection (250 mL and 1,000 mL, with a 500 mL size also in its table), 5% and 10% Glucose, and 5% Glucose with 0.9% sodium chloride.
- English-labeled. The letter states the imported products were English-labeled.
- Single authorized channel. No entity other than Baxter was authorized to import or distribute them.
- Container integrity. The letter includes visual-inspection language about particulates and bag defects and describes container integrity as essential to sterility.
Where it matters for labs, clinics and supply decisions
The documented lesson for supply teams is scope: a national “resolved” notice refers to named products, so inventory records should track each fluid and container separately rather than a single “saline” status. The sources also show why container integrity matters, since the Baxter letter treats an intact container as essential to sterility. Related background on how these items are stocked and kept sterile is in what an IV bag is, IV bag fluid types and institutional stocking, what a saline flush is and what an IV start kit is. For how FDA publishes shortage status, see the FDA drug shortage list, and for the wider procurement picture, hospital supply chain.
Common misunderstandings
- “The shortage was about saline in general.” FDA’s resolution is for sodium chloride 0.9% injection. Other IV fluids were still described as short.
- “Saline shortage and IV bag shortage are the same thing.” One is a drug listing, the other a device listing; empty IV bags were added to the Medical Device Shortages List on December 4, 2024.
- “Imported fluids were substandard.” The letter says only that they were not FDA-approved and imported temporarily under FDA coordination, with inspection instructions. It makes no quality claim beyond that.
- “The FDA statement blames Hurricane Helene.” It does not; the Baxter and Helene details come from AHA reporting.
FAQ
Is there still a shortage of normal saline solution?
Per FDA’s statement of August 8, 2025, the shortage of sodium chloride 0.9% injection products has resolved and the products were removed from the Current Shortages list. FDA said other IV fluids remained in shortage. Check the FDA Drug Shortage Database for the current status of a specific product.
What is the Baxter North Cove plant?
It is Baxter’s manufacturing site in North Cove, North Carolina, which AHA says Hurricane Helene damaged on September 27, 2024. By December 19, 2024, nearly all of its lines had restarted, according to AHA.
Was there an IV bag shortage as well as a saline shortage?
Yes, in the device category: on December 4, 2024 FDA added empty IV bags to the Medical Device Shortages List, with an estimated duration through March 2025, according to AHA.
Sources
- FDA, Statement from the FDA Commissioner announcing resolution of the IV saline solutions shortage, August 8, 2025 (checked November 1, 2026).
- Baxter, Important Prescribing Information letter (FDA-hosted PDF), October 21, 2024 (checked November 1, 2026).
- American Hospital Association, FDA announces end of IV saline solution shortage, August 11, 2025 (checked November 1, 2026).
